Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE versus HYGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE versus HYGROTON.
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE vs HYGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing sodium, chloride, and water excretion, and reducing peripheral vascular resistance.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
Oral: Initially enalapril 5 mg and HCTZ 12.5 mg once daily; titrate to maximum enalapril 20 mg / HCTZ 25 mg once daily.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
None Documented
None Documented
Enalaprilat: terminal 11 hours (multiple doses), prolonged in renal impairment (creatinine clearance <30 mL/min: 30-40 h). Hydrochlorothiazide: terminal 6-15 hours (mean 10 h), prolonged in renal impairment.
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
Enalapril: renal 60-80% (40-60% as enalaprilat, 20-40% as metabolites); fecal 20-40%. Hydrochlorothiazide: renal 95% (unchanged).
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic